| Identification | Back Directory | [Name]
HZ166 thyl 8-ethynyl-6-(2-pyridyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate | [CAS]
612527-56-7 | [Synonyms]
HZ166 thyl 8-ethynyl-6-(2-pyridyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-ethynyl-6-(2-pyridinyl)-, ethyl ester | [Molecular Formula]
C21H16N4O2 | [MDL Number]
MFCD32670717 | [MOL File]
612527-56-7.mol | [Molecular Weight]
356.38 |
| Hazard Information | Back Directory | [Uses]
HZ166 is a GABAA receptor subtype-selective benzodiazepine site agonist with preferential activity at α2- and α3-GABAA receptors. HZ166 shows anti-hyperalgesic effects[1]. HZ166 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [Biological Activity]
HZ-166 is a potentnon-sedative GABAA receptor subtype-selective benzodiazepine site agonist exhibits preference toward α2- and α3-GABAARs. HZ-166 exhibits antihyperalgesic properties in mice models of neuropathic and inflammatory painwithout sedation and motor impairment. | [References]
[1] Alessandra Di Lio, et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology. 2011 Mar;60(4):626-32. DOI:10.1016/j.neuropharm.2010.11.026 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|